CN1709309A - Chinese medicinal composition for treating edema and its preparing method - Google Patents
Chinese medicinal composition for treating edema and its preparing method Download PDFInfo
- Publication number
- CN1709309A CN1709309A CN 200510011852 CN200510011852A CN1709309A CN 1709309 A CN1709309 A CN 1709309A CN 200510011852 CN200510011852 CN 200510011852 CN 200510011852 A CN200510011852 A CN 200510011852A CN 1709309 A CN1709309 A CN 1709309A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- medicine composition
- present
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 206010030113 Oedema Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 64
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 210000000582 semen Anatomy 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 241000628997 Flos Species 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 241000222640 Polyporus Species 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000005325 percolation Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 abstract description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 6
- 241000521257 Hydrops Species 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000748223 Alisma Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 18
- 208000004880 Polyuria Diseases 0.000 description 15
- 230000035619 diuresis Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 241000053227 Themus Species 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 229960003883 furosemide Drugs 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 235000015091 medicinal tea Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000004910 pleural fluid Anatomy 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine composition for curing the diseases of watery distension, intrathoracic hydrops due to pulmonary carcinoma, ascites due to cirrhosis or liver cancer and renal edema, etc. with obvious therapeutic effect. Said Chinese medicine composition can be made into the conventional dosage forms of tablet, capsule, pills, tea preparation or granules preparation, and is made up by using 8 Chinese medicinal materials of tetrandra root, kansui root, genkwa flower, alisma tuber, astragalus root and ovate atractylodes root as raw material through a certain preparation process.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition, is a kind of Chinese medicine composition for the treatment of edema disease specifically, the invention still further relates to the preparation method of this Chinese medicine composition.
Background technology
Edema disease is the ascites pleural fluid of the medical problem of a universality, especially patients with advanced cancer, is one of four important topics in World Health Organization's cancer Comprehensive Treatment planning.A lot of patients form ascites pleural fluid owing to reasons such as portal hypertension and plasma albumin reductions in advanced lung cancer, the hepatocarcinoma case.Doctor trained in Western medicine adopts diuresis, replenishes method respite symptoms such as albumin, tapping at present, can not tackle the problem at its root.Because hydrops focus such as well ooze, the present is taken out bright length, need repeatedly drawing liquid, and side effect is big.Repeatedly draw water and can cause electrolyte, protein to lose in a large number, cause organism balance imbalance, have in addition cause inflammation, make the faster deterioration of the state of an illness, cause very big misery to patient.Differentiation of tcm viewpoint and organic conception think that the treatment edema disease will see the relation of " water " and body yang blood and qi: " the capable then water of gas is capable, and the capable water of blood is from logical ".By the conditioning to yang blood and qi, reinforcing body resistance is built up resistance, and promotes the human body self albumin synthetic, thereby suppresses the generation of edema.
In view of the medicine and the method for the treatment edema disease that does not have better curative effect at present, so a kind of repercussive Chinese medicine for oral administration of can anticancer relieving oedema or abdominal distension through diuresis or purgation again of demand.The inventor has been surprised to find that a kind of Chinese medicine composition for the treatment of edema disease, thereby has finished the present invention through animal experiment and clinical verification for many years.
Summary of the invention
Purpose of the present invention just provides a kind of Chinese medicine composition for the treatment of edema disease.
Another object of the present invention just provides the preparation method of this Chinese medicine composition.
The traditional Chinese medical science is thought edema diseases such as cancerous ascites pleural fluid and lung, spleen, kidney three through relevant, and spleen-asthenia with excessive damp then is an edema; Lung such as water source, the road of kidney such as water flowing, upper orifices closes that then lower orifices are obstructed, and then wet the spreading unchecked of water forms edema.Therefore, the lung qi retardance, dysuria is the dominant mechanism that edema takes place.On the basis of this traditional Chinese medical science understanding, establishing the treatment rule is the spleen strengthening and damp drying diuretic, the eliminating the pathogens from the lung promoting the circulation of QI to induce diuresis.Compositions of the present invention is exactly under the guidance of this treatment rule, selects for use the Chinese crude drug reasonable formula to be prepared from.
In one embodiment of the present invention, the effective ingredient of compositions of the present invention is to be that feedstock production forms by Radix Stephaniae Tetrandrae, Radix Kansui, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Polyporus, Rhizoma Alismatis, the Radix Astragali and the Rhizoma Atractylodis Macrocephalae, and wherein the Radix Stephaniae Tetrandrae inducing diuresis to remove edema is monarch drug; Radix Kansui, Flos Genkwa removing fluid-retention by purgation, Semen Lepidii (Semen Descurainiae) eliminating the pathogens from the lung row water is ministerial drug; The Polyporus eliminating dampness and diuresis, Rhizoma Alismatis diuresis, clearing away damp-heat, the diuresis of Radix Astragali QI invigorating, Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, dampness diuretic are adjuvant drug.The consumption of these preparation raw materials is (weight ratio): Radix Stephaniae Tetrandrae 150-225, Radix Kansui 60-120, Flos Genkwa 60-120, Semen Lepidii (Semen Descurainiae) 78-234, Polyporus 114-228, Rhizoma Alismatis 114-228, Radix Astragali 126-210, Rhizoma Atractylodis Macrocephalae 84-210.The preparation raw material and the consumption thereof of the effective ingredient of preferred Chinese medicine composition of the present invention are: Radix Stephaniae Tetrandrae 170-200, Radix Kansui 70-100, Flos Genkwa 70-100, Semen Lepidii (Semen Descurainiae) 100-150, Polyporus 140-180, Rhizoma Alismatis 140-180, Radix Astragali 140-180, Rhizoma Atractylodis Macrocephalae 100-140.More preferably the preparation raw material of the effective ingredient of Chinese medicine composition of the present invention and consumption thereof are: Radix Stephaniae Tetrandrae 180g, Radix Kansui 80g, Flos Genkwa 80g, Semen Lepidii (Semen Descurainiae) 120g, Polyporus 150g, Rhizoma Alismatis 150g, Radix Astragali 150g, Rhizoma Atractylodis Macrocephalae 120g.
The preparation of the effective ingredient of Chinese medicine composition of the present invention can be with above-mentioned raw material of Chinese medicine decocting together, filters, and obtains the water extract of above-mentioned raw materials; Perhaps above-mentioned raw material of Chinese medicine 60-95% alcohol reflux can be reclaimed ethanol and makes ethanol extract; Or the Rhizoma Atractylodis Macrocephalae, Radix Kansui be ground into fine powder, the Radix Astragali and Polyporus are thinly sliced, decocting, get the condensed water extract, use 70% ethanol extraction after Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder be broken into coarse powder, decompression recycling ethanol merges with above-mentioned water extracting liquid, continue to concentrate and make extract powder, add above-mentioned fine powder and obtain.
The effective ingredient of Chinese medicine composition of the present invention is preferably as follows preparation: the Rhizoma Atractylodis Macrocephalae, Radix Kansui are ground into fine powder; The Radix Astragali and Polyporus are thinly sliced, decocting 3 times, and 1.5 hours for the first time, second and third time each 1 hour, collecting decoction filters, and leaves standstill 12 hours, draws supernatant, and concentrating under reduced pressure becomes water extracting liquid; Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder are broken into coarse powder, make solvent, carry out percolation according to percolation with 70% ethanol, collect 8 times of percolates, decompression recycling ethanol merges with above-mentioned water extracting liquid, continue to concentrate and make extract powder, add the above-mentioned Rhizoma Atractylodis Macrocephalae and Radix Kansui fine powder, mixing promptly.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as tablet, capsule, granule, medicinal tea or pill etc.
Chinese medicine composition of the present invention has invigorating the spleen for eliminating dampness, the eliminating the pathogens from the lung circulation of qi promoting, and the repercussive effect of relieving oedema or abdominal distension through diuresis or purgation can be used for treating the exudative hydrothorax of pulmonary carcinoma, hepatocarcinoma or cirrhotic ascites, diseases such as renal edema, all right anticancer, adjuvant chemotherapy treatment cancer.
The specific embodiment
The sweet Yuan embodiment that relieves oedema or abdominal distension through diuresis or purgation:
Embodiment 1: the preparation of the watered pill of the present invention, honeyed pill
Take by weighing following raw materials in weight: Radix Stephaniae Tetrandrae 225g, Radix Kansui 120g, Flos Genkwa 120g, Semen Lepidii (Semen Descurainiae) 234g, Polyporus 228g, Rhizoma Alismatis 228g, Radix Astragali 210g, Rhizoma Atractylodis Macrocephalae 210g;
With Radix Stephaniae Tetrandrae, Radix Kansui, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Polyporus, Rhizoma Alismatis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae decocting together 2 times, each is 3 hours, collecting decoction, filter, obtain the water extract of described raw material, continue to be condensed into the thick paste that relative density is 1.10～1.45 (70 ℃), dry slightly, admix 20～80% Mel or water again, make water-honeyed pill, honeyed pill, the watered pill etc.
Embodiment 2: the preparation of tablet of the present invention
Take by weighing following raw materials in weight: Radix Stephaniae Tetrandrae 150g, Radix Kansui 60g, Flos Genkwa 60g, Semen Lepidii (Semen Descurainiae) 78g, Polyporus 114g, Rhizoma Alismatis 114g, Radix Astragali 126g, Rhizoma Atractylodis Macrocephalae 84g;
Radix Stephaniae Tetrandrae, Radix Kansui, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Polyporus, Rhizoma Alismatis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae are added 60% alcohol reflux 2 times together, each 2 hours, merge extractive liquid.Filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.10～1.25 (70 ℃), and drying is got 1 part of dry extract, make particle drying with the starch portion, add sodium carboxymethyl cellulose 0.3%, magnesium stearate 0.3%, tabletting, or directly pack, promptly get tablet of the present invention.
Embodiment 3: the preparation of capsule of the present invention
Take by weighing following raw materials in weight: Radix Stephaniae Tetrandrae 180g, Radix Kansui 80g, Flos Genkwa 80g, Semen Lepidii (Semen Descurainiae) 120g, Polyporus 150g, Rhizoma Alismatis 150g, Radix Astragali 150g, Rhizoma Atractylodis Macrocephalae 120g;
The Rhizoma Atractylodis Macrocephalae, Radix Kansui are ground into fine powder; The Radix Astragali and Polyporus are thinly sliced, decocting 3 times, and 1.5 hours for the first time, second and third time each 1 hour, collecting decoction filters, and leaves standstill 12 hours, draws supernatant, and concentrating under reduced pressure becomes water extracting liquid; Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder are broken into coarse powder, make solvent, carry out percolation according to percolation with 70% ethanol, collect 8 times of percolates, decompression recycling ethanol merges with above-mentioned water extracting liquid, continue to concentrate and make extract powder, add above-mentioned fine powder, mixing is made granule, 60 ℃ of oven dry, add 1～20% starch, mixing incapsulates, and promptly gets capsule of the present invention.
Embodiment 4: the preparation of granule of the present invention, medicinal tea
Take by weighing following raw materials in weight: Radix Stephaniae Tetrandrae 200g, Radix Kansui 100g, Flos Genkwa 100g, Semen Lepidii (Semen Descurainiae) 120g, Polyporus 150g, Rhizoma Alismatis 150g, Radix Astragali 150g, Rhizoma Atractylodis Macrocephalae 120g;
The Rhizoma Atractylodis Macrocephalae, Radix Kansui are ground into fine powder; The Radix Astragali and Polyporus are thinly sliced, decocting 3 times, and 1.5 hours for the first time, second and third time each 1 hour, collecting decoction filters, and leaves standstill 12 hours, draws supernatant, and concentrating under reduced pressure becomes water extracting liquid; Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder are broken into coarse powder, make solvent with 70% ethanol, carry out percolation according to percolation, collect 8 times of percolates, decompression recycling ethanol, merge with above-mentioned water extracting liquid, continue to concentrate and make extract powder, add above-mentioned fine powder, mixing is made granule, drying promptly gets granule; Or be pressed into bulk, make medicinal tea.
Below set forth the effect of this Chinese medicine composition by test.
Test material: medicine: capsule 0.28g/ grain of the present invention.Face with preceding water and be made into respective concentration.
Animal: C57 mouse inbred lines and wistar rat, all available from the shanghai Medicine Experimental Animal Center, cleaning level (0152, No. 0153), Kunming mouse is by Medical University Of Fujian's Experimental Animal Center supply (23-006).
Experimental example 1:The relieving distension of relieving oedema or abdominal distension through diuresis or purgation test
1. rat liver cancer (ascitic type) H
22: get 50 of female mices, body weight 22～24g, at first, every mouse peritoneal injection hepatocarcinoma H
22Cell suspension 10
7/ mm
30.2ml/ only, be divided into 5 groups at random by body weight, 10 every group, 3 groups of i.g Chinese medicine composition 0.5g/kg of the present invention respectively wherein, 1.0g/kg and 1.5g/kg, simple model group i.g normal saline (NS) 0.3ml/10g, more than equal every days 1 time, continuous 8 days; Positive control drug is selected 5-Fu25mg/kg for use, in d
1And d
3Each i.g1 time, totally 2 times.The 10th day course of treatment, mice claims to take off the execution of cervical vertebra method after the body weight on an empty stomach, earlier draw ascites with syringe, cut the abdominal cavity again open, blot ascites with degreasing cotton, weigh to mice more later on, and carry out statistical disposition (t check) and calculate average suppression ratio, the results are shown in Table one with the difference of secondary body weight ascites volume (g) as this Mus.
Cancer ascites suppression ratio (%)=(model group ascites volume-administration group ascites volume)/model group ascites volume * 100%
Table one, the present invention are to H
22Mice with tumor suppresses the ascites effect
| Group | Medicine (i.g) | The Mus number | Body weight (g) | Tumor heavy (g) | Press down tumor (%) | The P value | |
| ??d 0 | ??d 12 | ||||||
| ??1 | ??(NS) ??0.3ml/10g | ??10 | ??22.80 ??± ??0.60 | ??25.95 ??± ??0.85 | ??1.905 ??± ??0.809 | ||
| ??2 | ??5-Fu25mg/kg | ??10 | ??22.70 ??± ??0.56 | ??21.57 ??± ??0.77 | ??0.133 ??± ??0.083 | ??93.02 | ??＜ ??0.001 |
| ??3 | 0.5g/kg of the present invention | ??10 | ??22.65 ??± ??0.45 | ??25.44 ??± ??0.59 | ??1.556 ??± ??0.621 | ??18.32 | ??＞ ??0.05 |
| ??4 | 1.0g/kg of the present invention | ??10 | ??22.80 ??± ??0.60 | ??25.87 ??± ??0.71 | ??1.343 ??± ??0.155 | ??81.99 | ??＜ ??0.001 |
| ??5 | 1.5g/kg of the present invention | ??10 | ??22.75 ??± ??0.64 | ??25.92 ??± ??0.59 | ??0.231 ??± ??0.158 | ??87.87 | ??＜ ??0.001 |
The result shows, to liver ascites H
22Mice with tumor, Chinese medicine composition of the present invention have the good water effect that disappears, and wherein, 1.0g/kg group curative effect reaches 81.99%, P＜0.001, and 1.5g/kg group curative effect is higher.
2. diuretic test: get 50 of rats, female, body weight 283 ± 13g is divided into 5 groups at random, 10 every group.At first, the equal i.g normal saline of all rats (NS) 2.0ml/100g carries out the water load, and gently depresses abdominal part emptying residual urine.Get wherein 3 groups of rat difference i.g Chinese medicine composition 0.5g/kg of the present invention then, 1.0g/kg and 1.5g/kg; Positive control drug is selected furosemide 0.4g/kg i.g; Simple model group rat is i.g NS 2.0ml/100g then.Immediately rat is put into metabolic cage (every 1 cage) after the administration and collect 4 hours urine amounts.The result carries out the t check and calculates urine amount increment rate (%), the results are shown in Table two.
Urine amount increment rate (%)=(4 hours urine amounts of 4 hours urine amount-matched groups of administration group)/4 hours urine amount * 100% of matched group
Table two, the present invention are to rat diuresis amount
| Group | Medicine (i.g) | The Mus number | Body weight (g) | 4 hours urine amounts | Urine amount increment rate (%) | The P value |
| ??1 | ??(NS) ??2ml/10g | ??10 | ??283.1± ??8.5 | ??10.33± ??0.85 | ||
| ??2 | Furosemide 0.4g/kg | ??10 | ??283.1± ??8.6 | ??19.87± ??2.28 | ??92.35 | ?＜0.001 |
| ??3 | 0.5g/kg of the present invention | ??10 | ??283.1± ??9.1 | ??10.32± ??1.16 | ??-0.01 | ?＞0.05 |
| ??4 | 1.0g/kg of the present invention | ??10 | ??284.2± ??8.8 | ??11.93± ??1.76 | ??15.49 | ?＜0.05 |
| ??5 | 1.5g/kg of the present invention | ??10 | ??283.0± ??8.3 | ??12.38± ??1.20 | ??19.85 | ?＜0.01 |
The result shows that Chinese medicine composition of the present invention has certain diuresis more than dosage 1.0g/kg, and 4 hours urine amounts of 1.5g/kg group increase by 19.85%, P＜0.001, but with the positive control drug furosemide relatively, diuresis a little less than.
2 result of experiment show that Chinese medicine composition of the present invention is all relevant with its diuresis that is had and antitumaous effect to the detumescence effect of relieving oedema or abdominal distension through diuresis or purgation of cancer of late stage individuality in the test example.
Experimental example 2:Press down tumor and synergism test
1. sarcoma S
180: get 70 of mices, male, body weight 18.0～19.5g is at first in the left front armpit subcutaneous vaccination S of every mice
180Cell suspension 10
7/ mm
3* 0.2ml/ only and carries out random packet by body weight, and 10 every group, totally 7 groups.Wherein 3 groups of mices are distinguished i.g Chinese medicine composition 0.5g/kg of the present invention, 1.0g/kg and 1.5g/kg, every day 1 time, continuous 11 days; 1 (d of 2 groups of difference i.g positive control drug cyclophosphamide (CTX) 25mg/kg
1) and 2 (d
1And d
3Each is 1 time); In the time of 1 group of i.g Chinese medicine composition 1.0g/kg of the present invention (qd * 11), in d
1Whether i.g CTX25mg/kg 1 time, being used to observe the two logotype has synergism.Simple model group mice i.g normal saline (NS) 0.3ml/10g, qd * 11 time.24 hours (d behind the last medicine
12) claim that on an empty stomach taking off the cervical vertebra method after the body weight puts to death, cut open and get the tumor piece and put into analytical balance and weigh.The result carries out the t check, calculates average tumour inhibiting rate.Test repeats 3 times, the results are shown in Table three.
Table three, the present invention are to S
180The tumor-inhibiting action of mice with tumor
| Batch | Group | Medicine (i.g) | The Mus number | Body weight (g) | Tumor heavy (g) | Press down tumor (%) | The P value | |
| ??d 0 | ??d 12 | |||||||
| ??I | ??1 | NS0.3ml/10g 11 times | ??10 | ??18.55 ??± ??0.35 | ??25.99 ??± ??0.72 | ??1.836 ??± ??0.205 | ||
| ??2 | CTX25mg/kg 1 time | ??10 | ??18.60 ??± ??0.30 | ??24.79 ??± ??0.73 | ??1.483 ??± ??0.541 | ??19.23 | ??＞ ??0.05 | |
| ??3 | CTX25mg/kg 2 times | ??10 | ??18.60 ??± ??0.30 | ??18.72 ??± ??0.68 | ??0.282± ??0.137 | ??84.64 | ??＜ ??0.001 | |
| ??4 | 0.5g/kg of the present invention 11 times | ??10 | ??18.65 ??± ??0.39 | ??25.53 ??± ??0.54 | ??1.682± ??0.611 | ??8.39 | ??＞ ??0.05 | |
| ??5 | 1.0g/kg of the present invention 11 times | ??10 | ??18.60 ??0.30 | ??25.62 ??± ??0.70 | ??1.003± ??0.4730.001 | ??45.37 | ??＜ ??0.001 | |
| ??6 | 1.5g/kg of the present invention 11 times | ??10 | ??18.55 ??± ??0.27 | ??25.81 ??± ??0.64 | ??0.623± ??0.174 | ??66.07 | ??＜ ??0.001 | |
| ??7 | Group 2+ group 4 | ??10 | ??18.55 ??± ??0.35 | ??25.60 ??± ??0.43 | ??0.771± ??0.329 | ??58.01 | ??＜ ??0.001 | |
| ??II | ??1 | NS0.3ml/10g 11 times | ??10 | ??19.99 ??± ??0.60 | ??26.12 ??± ??0.71 | ??1.691± ??0.113 | ||
| ??2 | CTX25mg/kg 1 time | ??10 | ??19.97 ??± ??0.64 | ??24.23 ??± ??0.80 | ??1.271± ??0.292 | ??24.84 | ??＜ ??0.01 | |
| ??3 | 0.5g/kg of the present invention 11 times | ??10 | ??20.01 ??± ??0.65 | ??25.89 ??± ??0.40 | ??1.587± ??0.064 | ??6.12 | ??＜ ??0.05 | |
| ??4 | 1.0g/kg of the present invention 11 times | ??10 | ??20.01 ??± ??0.66 | ??25.84 ??0.84 | ??1.437± ??0.074 | ??15.02 | ??＜ ??0.001 |
| ??5 | 1.5g/kg of the present invention 11 times | ??10 | ??19.95 ??± ??0.56 | ??26.22 ??± ??0.72 | ??0.751± ??0.287 | ??55.59 | ??＜ ??0.001 | |
| ??6 | Group 2+ group 4 | ??10 | ??20.01 ??± ??0.57 | ??25.84 ??± ??0.58 | ??0.537± ??0.241 | ??68.24 | ??＜ ??0.001 | |
| ??III | ??1 | NS0.3ml/10g 11 times | ??10 | ??20.02 ??± ??0.95 | ??26.67 ??± ??0.31 | ??1.507± ??0.126 | ||
| ??2 | CTX25mg/kg 1 time | ??10 | ??19.94 ??± ??0.95 | ??23.76 ??± ??1.53 | ??1.372± ??0.141 | ??8.96 | ??＞ ??0.05 | |
| ??3 | 0.5g/kg of the present invention 11 times | ??10 | ??19.97 ??± ??0.95 | ??26.48 ??± ??0.45 | ??1.466± ??0.114 | ??0.27 | ??＞ ??0.05 | |
| ??4 | 1.0g/kg of the present invention 11 times | ??10 | ??19.99 ??± ??0.91 | ??26.35 ??± ??0.43 | ??1.334± ??0.229 | ??11.48 | ??＜ ??0.05 | |
| ??5 | 1.5k/kg of the present invention 11 times | ??10 | ??19.93 ??± ??0.90 | ??24.69 ??± ??0.45 | ??0.925± ??0.113 | ??38.62 | ??＜ ??0.001 | |
| ??6 | Group 2+ group 4 | ??10 | ??19.86 ??± ??0.88 | ??26.57 ??± ??0.58 | ??0.703± ??0.097 | ??53.35 | ??＜ ??0.001 |
The result shows that Chinese medicine composition of the present invention is in dosage 1.5g/kg continuous i.g11 day, to S
180In the intravital growth of mice certain inhibitory action is arranged, the suppression ratio of 3 tests reaches 38.62～66.07%, compares P＜0.001 with model group (group 1).And the suppression ratio of 1.0g/kg group is lower, only 11.48～45.37%, but when it and chemotherapeutics CTX (25mg/kg1 time) drug combination, curative effect then significantly improves, and can reach 53.35～68.24%, all is higher than the curative effect after two medicines are taken separately, compare with group 2, P＜0.001, prompting is pressing down aspect the tumor, and the two has synergism.
2.Lewis pulmonary carcinoma: get C
5760 of mices, male, body weight 17.5～19.5g is at first in the left front armpit subcutaneous vaccination Lewis cell suspension 10 of every mice
7/ mm
3* 0.2ml/ only and carries out random packet by body weight, and 10 every group, totally 6 groups.Wherein 3 groups of mices are distinguished i.g Chinese medicine composition 0.5g/kg of the present invention, 1.0g/kg and 1.5g/kg, every day 1 time, continuous 12 days; 1 group of mice i.g CTX25mg/kg, the same day 1 time; In the time of drug combination group i.g Chinese medicine composition 1.0g/kg of the present invention (continuous 12 days), the first day adds CTX25mg/kg1 time.Simple model group i.g normal saline (NS) 0.3ml/10g, every day 1 time, continuous 12 days.Behind the last medicine 24 hours, claim that on an empty stomach taking off the cervical vertebra method after the body weight puts to death, cut open and get the tumor piece and put into analytical balance and weigh.The result carries out the t check, calculates average tumour inhibiting rate, and test repeats 3 times, the results are shown in Table four.
Cancer suppressing ratio (%)=(matched group tumor weight-administration group tumor is heavy)/matched group tumor heavy * 100%
Table four, the present invention are to C
57The inhibitory action of Lewis lung cancer in the mice body
| Batch | Group | Medicine (i.g) | The Mus number | Body weight (g) | Tumor heavy (g) | Press down tumor (%) | The P value | |
| ??d 0 | ??d 12 | |||||||
| ??I | ??1 | NS0.3ml/10g 11 times | ??10 | ??18.60 ??± ??0.66 | ??23.50 ??± ??0.89 | ??2.003 ??± ??0.379 | ||
| ??2 | CTX25mg/kg 2 times | ??10 | ??18.55 ??± ??0.69 | ??19.65 ??± ??1.07 | ??0.957 ??± ??0.205 | ??52.22 | ??＜ ??0.001 | |
| ??3 | 0.5g/kg of the present invention 11 times | ??10 | ??18.55 ??± ??0.79 | ??24.00 ??± ??0.89 | ??1.946 ??± ??0.296 | ??2.85 | ??＞ ??0.05 | |
| ??4 | 1.0g/kg of the present invention 11 times | ??10 | ??18.55 ??± ??0.79 | ??23.90 ??± ??0.83 | ??1.639 ??± ??1.240 | ??18.17 | ??＜ ??0.05 | |
| ??5 | 1.5g/kg of the present invention 11 times | ??10 | ??18.50 ??± ??0.63 | ??23.65 ??± ??0.95 | ??1.407 ??± ??0.233 | ??29.76 | ??＜ ??0.001 | |
| ??6 | Group 2+ group 4 | ??10 | ??18.65 ??± ??0.57 | ??22.28 ??± ??1.23 | ??0.759 ??± ??0.213 | ??62.11 | ??＜ ??0.001 | |
| ??II | ??1 | NS0.3ml/10g 11 times | ??10 | ??18.65 ??± ??0.45 | ??25.85 ??± ??0.87 | ??1.307 ??± ??0.225 | ||
| ??2 | CTX25mg/kg 2 times | ??10 | ??18.80 ??± ??0.51 | ??22.27 ??± ??0.77 | ??0.797 ??± ??0.380 | ??39.02 | ??＜ ??0.01 | |
| ??3 | 0.5g/kg of the present invention 11 times | ??10 | ??18.75 ??± ??0.51 | ??25.66 ??± ??0.84 | ??1.264 ??± ??0.182 | ??3.60 | ??＞ ??0.05 | |
| ??4 | 1.0g/kg of the present invention 11 times | ??10 | ??18.70 ??± ??0.56 | ??25.63 ??± ??0.71 | ??1.132 ??± ??0.187 | ??12.62 | ??＞ ??0.05 | |
| ??5 | 1.5g/kg of the present invention 11 times | ??10 | ??18.70 ??± ??0.26 | ??24.99 ??± ??1.03 | ??0.995 ??± ??0.156 | ??23.87 | ??＜ ??0.01 |
| ??III | ??1 | NS0.3ml/10g 11 times | ??10 | ??18.25 ??± ??0.51 | ??25.33 ??± ??0.72 | ??1.617 ??± ??0.269 | ||
| ??2 | CTX25mg/kg 2 times | ??10 | ??18.20 ??± ??0.71 | ??20.21 ??± ??1.08 | ??1.066 ??± ??0.291 | ??33.95 | ??＜ ??0.001 | |
| ??3 | 0.5g/kg of the present invention 11 times | ??10 | ??18.25 ??± ??0.83 | ??24.63 ??± ??1.69 | ??1.453 ??± ??0.253 | ??10.14 | ??＞ ??0.05 | |
| ??4 | 1.0g/kg of the present invention 11 times | ??10 | ??18.25 ??± ??0.68 | ??24.62 ??± ??1.01 | ??1.239 ??± ??0.234 | ??23.38 | ??＜ ??0.01 | |
| ??5 | 1.5g/kg of the present invention 11 times | ??10 | ??18.25 ??± ??0.72 | ??24.22 ??± ??1.13 | ??1.009 ??± ??0.200 | ??37.60 | ??＜ ??0.001 |
The result shows that Chinese medicine composition of the present invention has certain inhibitory action to the growth of Mice Bearing Lewis Lung Cancer, and the highest cancer suppressing ratio of 1.5g/kg group is 37.60%, P＜0.001.The drug combination result of the test shows, Chinese medicine composition of the present invention has obvious role in synergism (P＜0.05) with chemotherapeutics CTX aspect the tumor pressing down
Experimental example 3:Influence to leukocyte and immune organ
Get 50 of mices, male, body weight 20.0 ± 1.5g, random packet, 10 every group, totally 5 groups.Wherein 2 groups of mices are distinguished i.g Chinese medicine composition 0.75g/kg of the present invention and 1.5g/kg, every day 1 time, continuous 12 days; 1 group of i.g CTX50mg/kg d
1And d
5Each 1 time (totally 2 times); 1 group at i.g Chinese medicine composition 1.5g/kg of the present invention in continuous 12 days, in d
1And d
5Each i.g CTX50mg/kg, 1 time (totally 2 times); Simple model group is i.g normal saline (NS) 0.3ml/10g then, every day 1 time, continuous 12 days.24 hours (d behind the last medicine
13), each mice is got blood and gets thymus and liver is weighed for surveying leukocyte count, cuing open then behind eyeball after claiming on an empty stomach body weight, and calculate thymus index (mg/g) and the spleen index (mg/kg%) of mice respectively, with simple model group relatively, the result carries out the t check, the results are shown in Table five, table six.
Table 5, the present invention be to the mice peripheral leukocytes, the influence of thymus and spleen weight
| Group | Medicine (i.g) | The Mus number | Body weight (g) | ?WBC ?10 3/mm 3 | Thymus index (mg/g) | Spleen index (mg/kg%) | |
| ??d 0 | ??d 12 | ||||||
| 1 | NS0.3ml/10g 12 times | ??10 | ??21.18 ??± ??1.14 | ??26.46 ??± ??0.89 | ??9.596 ??± ??1.946 | ??2.572 ??± ??0.285 | ??3.014±0.37 |
| 2 | CTX50mg/kg 2 times | ??10 | ??21.12 ??± ??1.14 | ??21.00 ??± ??1.31 | ??4.113 ??± ??1.610 | ??0.896 ??± ??0.226 | ??1.361±0.262 |
| 3 | 0.5g/kg of the present invention 12 times | ??10 | ??21.11 ??± ??1.08 | ??23.69 ??± ??2.70 | ??9.156 ??± ??1.516 | ??2.712 ??± ??0.459 | ??3.094±0.388 |
| 4 | 1.0g/kg of the present invention 12 times | ??10 | ??21.12 ??± ??1.10 | ??25.75 ??± ??1.01 | ??9.633 ??± ??1.610 | ??2.810 ??± ??0.086 | ??3.191±0.341 |
| 5 | 1.5g/kg of the present invention 12 times | ??10 | ??21.12 ??± ??1.14 | ??23.25 ??± ??1.71 | ??4.841 ??± ??1.400 | ??1.074 ??± ??0.303 | ??1.606±0.232 |
Table six, significance test (P value)
| Group | Number of animals | Compare (P value) with negative control | ||
| WBC | Thymus index | Spleen index | ||
| NS0.3 | ?10 | |||
| Ml/10g 12 times | ||||
| CTX50 mg/kg 2 times | ??10 | ??P＜0.001 | ??P＜0.001 | ??P＜0.001 |
| 1.5g/kg of the present invention 12 times | ??10 | ??P＜0.001 | ??P＜0.001 | ??P＜0.001 |
The result shows, Chinese medicine composition of the present invention is to the murine interleukin number, and immune organ thymus and spleen all do not have obvious inhibitory action, during with chemotherapeutics CTX drug combination, leukopenia, thymus and splenatrophy etc. that CTX is brought out not only further do not worsen, and alleviate to some extent on absolute value.Be appreciated that the foregoing description and experimental example just in order to set forth the present invention better, and do not play any qualification effect.
Claims (8)
1, a kind of Chinese medicine composition for the treatment of edema disease, it is made up of effective ingredient and/or acceptable accessories, it is characterized in that its contained effective ingredient is to be made by the following weight proportion raw material: Radix Stephaniae Tetrandrae 150-225, Radix Kansui 60-120, Flos Genkwa 60-120, Semen Lepidii (Semen Descurainiae) 78-234, Polyporus 114-228, Rhizoma Alismatis 114-228, Radix Astragali 126-210, Rhizoma Atractylodis Macrocephalae 84-210.
2, according to the described Chinese medicine composition of claim 1, wherein said raw material weight ratio is: Radix Stephaniae Tetrandrae 170-200, Radix Kansui 70-100, Flos Genkwa 70-100, Semen Lepidii (Semen Descurainiae) 100-150, Polyporus 140-180, Rhizoma Alismatis 140-180, Radix Astragali 140-180, Rhizoma Atractylodis Macrocephalae 100-140.
3, according to the described Chinese medicine composition of claim 1, wherein said raw material weight ratio is: Radix Stephaniae Tetrandrae 180, Radix Kansui 80, Flos Genkwa 80, Semen Lepidii (Semen Descurainiae) 120, Polyporus 150, Rhizoma Alismatis 150, the Radix Astragali 150, the Rhizoma Atractylodis Macrocephalae 120.
4, according to the described Chinese medicine composition of claim 1, it is regular dosage forms such as capsule, tablet, pill or granule.
5, the preparation method of each described Chinese medicine composition of claim 1-4, it comprise described raw material of Chinese medicine pulverized after together the decocting after-filtration obtain the water extract of described raw material, again and/or and mixing acceptable accessories.
6, the preparation method of each described Chinese medicine composition of claim 1-4, it comprises pulverizes back 60-95% alcohol reflux with described raw material of Chinese medicine, and recovery ethanol makes ethanol extract, again and/or and mixing acceptable accessories.
7, the preparation method of each described Chinese medicine composition of claim 1-4, it comprises the Rhizoma Atractylodis Macrocephalae, Radix Kansui is ground into fine powder; The Radix Astragali and Polyporus are thinly sliced, and decocting gets the condensed water extract; Use the 60-95% ethanol extraction after Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder be broken into coarse powder, decompression recycling ethanol merges with above-mentioned water extracting liquid, continues to concentrate and make extract powder, add above-mentioned fine powder and obtain effective ingredient, again and/or and mixing acceptable accessories.
8, according to the described preparation method of claim 6, it comprises the Rhizoma Atractylodis Macrocephalae, Radix Kansui is ground into fine powder; The Radix Astragali and Polyporus are thinly sliced, decocting 3 times, and 1.5 hours for the first time, second and third time each 1 hour, collecting decoction filters, and leaves standstill 12 hours, draws supernatant, and concentrating under reduced pressure becomes water extracting liquid; Radix Stephaniae Tetrandrae, Flos Genkwa, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis powder are broken into coarse powder, make solvent, carry out percolation according to percolation with 70% ethanol, collect 8 times of percolates, decompression recycling ethanol merges with above-mentioned water extracting liquid, continue to concentrate and make extract powder, add above-mentioned fine powder, mixing is made granule, 60 ℃ of oven dry, add 1-20% starch, mixing incapsulates, and makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100118521A CN1296081C (en) | 2005-06-02 | 2005-06-02 | Chinese medicinal composition for treating edema and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100118521A CN1296081C (en) | 2005-06-02 | 2005-06-02 | Chinese medicinal composition for treating edema and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709309A true CN1709309A (en) | 2005-12-21 |
| CN1296081C CN1296081C (en) | 2007-01-24 |
Family
ID=35705641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100118521A Expired - Fee Related CN1296081C (en) | 2005-06-02 | 2005-06-02 | Chinese medicinal composition for treating edema and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296081C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716299A (en) * | 2012-06-25 | 2012-10-10 | 李良 | Areca peel herbal soup for treating edema and method for preparing areca peel herbal soup |
| CN103520523A (en) * | 2013-09-09 | 2014-01-22 | 吴承菊 | Traditional Chinese medicine composition for treating edema |
| CN103610867A (en) * | 2013-11-28 | 2014-03-05 | 纪召萌 | Medicament for treating stranguria and preparation method thereof |
| CN103861017A (en) * | 2014-04-11 | 2014-06-18 | 胡海波 | Traditional Chinese medicinal composition for treating tuberculous pleural effusion and preparation method of composition |
| CN104758499A (en) * | 2015-04-21 | 2015-07-08 | 铜仁学院 | Compound Miao-national medicine for treating edema |
| CN108272925A (en) * | 2018-04-02 | 2018-07-13 | 赵淑芳 | It is a kind of treat cirrhotic ascites, pleural effusions and ascites medicinal powder and preparation method thereof |
| US10258663B2 (en) * | 2017-08-04 | 2019-04-16 | Chen-Yu Lee | Method for treating malignant pleural effusion |
| CN111110759A (en) * | 2018-11-01 | 2020-05-08 | 北京中西联盟肿瘤医学研究院(普通合伙) | Water-eliminating ointment for treating cancerous ascites and preparation method thereof |
| CN113842419A (en) * | 2021-11-02 | 2021-12-28 | 柳州市中医医院(柳州市壮医医院) | Traditional Chinese medicine composition for treating nephrotic syndrome edema of children and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230193C (en) * | 2003-07-01 | 2005-12-07 | 冯春和 | Water-purging pill comprising genkwanin and kansui root |
-
2005
- 2005-06-02 CN CNB2005100118521A patent/CN1296081C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716299A (en) * | 2012-06-25 | 2012-10-10 | 李良 | Areca peel herbal soup for treating edema and method for preparing areca peel herbal soup |
| CN102716299B (en) * | 2012-06-25 | 2014-02-26 | 李良 | Areca peel herbal soup for treating edema and method for preparing areca peel herbal soup |
| CN103520523A (en) * | 2013-09-09 | 2014-01-22 | 吴承菊 | Traditional Chinese medicine composition for treating edema |
| CN103520523B (en) * | 2013-09-09 | 2016-02-24 | 吴承菊 | A kind of Chinese medicine composition for the treatment of edema |
| CN103610867A (en) * | 2013-11-28 | 2014-03-05 | 纪召萌 | Medicament for treating stranguria and preparation method thereof |
| CN103861017A (en) * | 2014-04-11 | 2014-06-18 | 胡海波 | Traditional Chinese medicinal composition for treating tuberculous pleural effusion and preparation method of composition |
| CN103861017B (en) * | 2014-04-11 | 2016-05-25 | 刘梅 | Be used for the treatment of Chinese medicine composition of tuberculous pleural effusion and preparation method thereof |
| CN104758499A (en) * | 2015-04-21 | 2015-07-08 | 铜仁学院 | Compound Miao-national medicine for treating edema |
| US10258663B2 (en) * | 2017-08-04 | 2019-04-16 | Chen-Yu Lee | Method for treating malignant pleural effusion |
| CN108272925A (en) * | 2018-04-02 | 2018-07-13 | 赵淑芳 | It is a kind of treat cirrhotic ascites, pleural effusions and ascites medicinal powder and preparation method thereof |
| CN111110759A (en) * | 2018-11-01 | 2020-05-08 | 北京中西联盟肿瘤医学研究院(普通合伙) | Water-eliminating ointment for treating cancerous ascites and preparation method thereof |
| CN113842419A (en) * | 2021-11-02 | 2021-12-28 | 柳州市中医医院(柳州市壮医医院) | Traditional Chinese medicine composition for treating nephrotic syndrome edema of children and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1296081C (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1296081C (en) | Chinese medicinal composition for treating edema and its preparing method | |
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| CN101049424A (en) | Medication for treating infection in respiratory system | |
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN1159050C (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN1943713A (en) | A Chinese traditional medicinal composition for treating diabetes and its preparation method | |
| CN1285377C (en) | Gynecological inflammation treating medicine and its preparation method | |
| CN1264540C (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN1302799C (en) | Oral Chinese medicinal composition for treating virus myocarditis | |
| CN1246024C (en) | Prepared Chinese medicine for treating acute and chronic urinary infection | |
| CN103157048B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN104998085A (en) | Chinese herbal compound composition capable of enhancing immune function and preparation method thereof | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN101028482A (en) | Stomach-clearing pill | |
| CN101049349A (en) | Chinese traditional medicine preparation in use for treating liver and gall disease, and preparation method | |
| CN1274338C (en) | Traditional Chinese medicine for treating aplastic anemia and its preparation process | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1233383C (en) | Chinese medicinal preparation for treating prostate disease and its preparation method | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process | |
| CN102258593B (en) | Chinese medicinal composition for adjuvant treatment of tumors and preparation method and application thereof | |
| CN109172756B (en) | A Chinese medicinal composition for treating hepatopathy | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070124 |